HC Wainwright Reiterates “Buy” Rating for Atyr PHARMA (NASDAQ:ATYR)

Atyr PHARMA (NASDAQ:ATYR)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $35.00 price target on the stock.

ATYR has been the topic of a number of other research reports. Wells Fargo & Company began coverage on Atyr PHARMA in a research report on Friday, October 4th. They set an “overweight” rating and a $17.00 price target on the stock. Jefferies Financial Group started coverage on shares of Atyr PHARMA in a report on Thursday, September 5th. They set a “buy” rating and a $9.00 price objective on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Atyr PHARMA in a research note on Wednesday, August 14th.

Atyr PHARMA Stock Performance

NASDAQ ATYR traded down $0.19 during trading on Tuesday, reaching $3.37. 240,495 shares of the company traded hands, compared to its average volume of 582,481. The stock has a 50 day moving average price of $2.79. Atyr PHARMA has a 1-year low of $1.14 and a 1-year high of $3.80. The firm has a market capitalization of $282.88 million, a P/E ratio of -3.59 and a beta of 1.07. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). Equities research analysts expect that Atyr PHARMA will post -0.89 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.